ClinicalTrials.gg
RecruitingNCT07684612Updated Oct 1, 2026

A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)

A Phase 3 interventional study of Mocertatug rezetecan (Mo-Rez) and Carboplatin in Ovarian Neoplasms, sponsored by GlaxoSmithKline. Recruiting at 9 sites in 4 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 1, 2026Now RecruitingFirst sites in Australia, Canada and South Korea+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
690
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies in Ovarian Neoplasms by GlaxoSmithKline — 5 open to participants now, 7 under way, 5 of them phase 3. Ovarian Neoplasms · GlaxoSmithKline.

Planned enrollment
4th of 30
690 · median 77
Started
2026
with 2 others
Phase 3
7 of 31
3 open now
Registered
30th of 31
by date

Among the 31 studies in Ovarian Neoplasms by GlaxoSmithKline, this one is the 4th largest by planned enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2026, is one of 7 in phase 3, and was the 30th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

5 of the 31 studies in Ovarian Neoplasms by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Ovarian Neoplasms by GlaxoSmithKline, or all of them as a file.
02

Study summary

This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) in combination with bevacizumab works in treating platinum-sensitive ovarian cancer compared to standard treatments by checking whether it makes cancers smaller or disappear completely and if it helps participants live longer. The study also assesses whether Mo-Rez in combination with bevacizumab is safe and tolerated well by participants compared to standard treatments and aims to provide a better understanding of the main side effects of Mo-Rez.

03

Conditions studied

  • Ovarian Neoplasms

Browse trials for

Keywords

  • Platinum-Sensitive Ovarian Cancer (PSOC)
  • Mocertatug Rezetecan
  • Mo-Rez
  • GSK5733584
  • Bevacizumab
  • Platinum Doublet
  • Carboplatin
  • Paclitaxel
  • Gemcitabine
  • Pegylated Liposomal Doxorubicin (PLD)
  • Antibody-Drug Conjugate
  • BEHOLD-Ovarian02
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is at least 18 years of age and the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the Form (ICF).
  • Has epithelial ovarian, primary peritoneal, or fallopian-tube cancer with a confirmed diagnosis of high grade serous, high grade endometrioid, clear cell carcinoma, or carcinosarcoma.
  • Has recurrent or progressive disease after completion of at least 1 and a maximum of 2 previous lines of systemic anticancer therapy. Recurrent or progressive disease should be determined based on radiographic assessment according to 1.1 per investigator and/or clinical assessment of disease progression by investigator. are defined as follows:

    • Adjuvant ± is considered one line of therapy.
    • Maintenance therapy (e.g., bevacizumab, Poly ADP-ribose polymerase inhibitor [PARPi]) will be considered as part of the preceding line of therapy (i.e., not counted independently).
    • Therapy changed to another agent in the same class due to toxicity, in the absence of progression, will be considered as part of the same line (i.e., not counted independently).
    • Unplanned addition or switching to a new drug in a different class is considered a separate line of therapy
    • Hormonal therapy will be counted as a separate line of therapy unless it was given as maintenance.
  • Has platinum-sensitive disease and is suitable for platinum doublet chemotherapy with bevacizumab for the treatment of recurrent disease. Platinum sensitive disease is defined as recurrent or progressive disease >6 months after last dose of platinum-based chemotherapy.
  • Has documented results of local testing (compliant to local regulations) for tumor and/or germline Breast Cancer Gene (BRCA1 and BRCA2) mutation. Participants with a known tumor or germline deleterious BRCA1 or BRCA2 mutation must have previously received PARPi maintenance therapy, alone or in combination with bevacizumab, if the participant was considered a candidate for this treatment and the treatment is locally available.
  • Has provided a Formalin Fixed Paraffin Embedded (FFPE) tumor tissue sample sufficient for the central assessment of B7 homolog 4 protein (B7-H4) expression, with the result of B7-H4 expression testing available prior to the date of randomization.
  • Is willing to use adequate . Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • A female participant is eligible to participate if they are not pregnant or breastfeeding, and 1 of the following conditions applies:

    • Is a Participant of Non- (PONCBP). OR
    • Is a Participant of Childbearing Potential (POCBP) and using a contraceptive method that is highly effective (with a failure rate of \<1% per year), preferably with low user dependency, 30 days prior to Cycle 1 Day 1 (C1D1) and during the study intervention period and for at least 8 months after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator should evaluate the potential for contraceptive method failure (e.g., noncompliance, recently initiated) in relationship to the first dose of study intervention.
  • A POCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 24 hours before the first dose of study intervention.
  • Is capable of giving signed informed consent including compliance with the requirements and restrictions listed in the ICF and in this protocol.
  • Has an (ECOG) performance status of 0 or 1.
  • Has adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • Plans to undergo interval secondary cytoreductive surgery for recurrent PSOC during induction therapy (platinum doublet and bevacizumab).
  • Has a (except disease under study) that has progressed or required active treatment within the past 36 months prior to the date of randomization, except for basal cell or squamous cell carcinomas of the skin or in situ carcinomas (e.g., breast, cervix, bladder) that have been resected with no evidence of disease, or that is otherwise considered cured by the investigator.
  • Has known sensitivity to study intervention components or or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.
  • Has untreated brain or central nervous system (CNS) metastases or brain/ that have progressed (e.g., evidence of new or enlarging brain metastasis or new neurologic symptoms attributable to brain/CNS metastases). Participants with previously treated and clinically stable brain/CNS metastases and who have completed all therapy for ≥14 days prior to the date of C1D1 are not excluded from participation.
  • Has any evidence of current Interstitial Lung Disease (ILD) or pneumonitis or a prior history of ILD or non-infectious pneumonitis.
  • Has ongoing adverse reaction(s) from prior therapy that has (have) not recovered to Grade ≤1 or to the baseline status preceding prior therapy, excluding alopecia, hearing loss, vitiligo, endocrinopathy managed with replacement therapy, Grade 2 neuropathy or that the investigator, with the agreement of the sponsor, considers to be not for the tolerability of study intervention in the current clinical study.
  • Has any serious and/or unstable medical condition (including infection) or any serious and/or unstable psychiatric disorder or other condition(s) (including laboratory assessment abnormalities) that could interfere with the participant's safety, obtainment of , or compliance to the study procedures.
  • Has clinically significant wound healing complications or incompletely healed wounds.
  • Has a history or evidence of gastrointestinal perforation, tracheoesophageal fistula, or any Grade 4 fistula; has gastrointestinal fistula, visceral fistula, or abdominal abscess within 6 months prior to the date of C1D1; has osteonecrosis of the jaw.
  • Has evidence of recto-sigmoid involvement by pelvic examination or bowel involvement on computed tomography (CT) scan or clinical symptoms of bowel obstruction.
  • Has clinically significant bleeding symptoms, significant bleeding tendency, or bleeding tumors within 30 days prior to the date of C1D1.
  • Has congenital bleeding diathesis, acquired coagulopathy, recent pulmonary hemorrhage/hemoptysis (>2.5 mL of red blood or a half teaspoon) within 3 months prior to the date of C1D1.
  • Has had any major surgery within 28 days prior to the date of C1D1 or history of focal radiotherapy within 21 days prior to the date of C1D1.
  • Has received treatment with an agent within 30 days prior to the date of C1D1.
  • Has ever received prior therapy with topoisomerase 1 inhibitor [Topo1i] (e.g., topotecan) or antibody-Drug Conjugate (ADC) with a Topo1i warhead, or B7-H4 targeted therapy.
  • Has received treatment with any cytotoxic chemotherapy drugs or other antitumor drugs (including endocrine therapy, molecular targeted therapy, immunotherapy or biotherapy) within 30 days or 5 half-lives, whichever is shorter, prior to the date of C1D1; or need to continue these drugs during study participation.
  • Has received treatment with inhibitors of P-glycoprotein (P-gp), or Breast Cancer Resistant Protein (BCRP), or Organic Anion Transporting Polypeptides 1B1/1B3 (OATP1B1/1B3) within 7 days prior to the date of C1D1. Has received treatment with inducers of P-gp within 14 days prior to the date of C1D1.
  • Has received any within 30 days prior to the date of C1D1.
  • Has received any transfusion of blood products (including or red blood cells) or administration of colony-stimulating factors (including granulocyte colony stimulating factor, granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 14 days prior to date of C1D1.
  • Has a history within 12 months prior to screening of clinically significant or uncontrolled cardiac disease, acute myocardial infarction, Class III or IV congestive heart failure, or clinically significant arrhythmia not controlled by standard of care therapy.
  • Has baseline (LVEF) \<50% or less than institutional lower limit of normal.
  • Has clinically significant abnormal blood pressure according to investigator assessment, or inadequately treated and uncontrolled hypertension including history of hypertensive crisis; hypertensive encephalopathy; or adjustment of antihypertensive medications due to poor blood pressure control within 14 days prior to the date of C1D1.
  • Has a history of nephrotic syndrome or Grade 3 proteinuria.
  • Meets the following criteria for proteinuria during screening assessments: ≥2+ proteinuria on urine dipstick and 24-hour urine collection demonstrating ≥1 g of urine protein in 24 hours.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
690 participants (estimated)

Study arms

  • Experimental
    Mocertatug rezetecan (Mo-Rez) + Bevacizumab

    Participants will receive Mo-Rez + bevacizumab.

    Drug: Mocertatug rezetecan (Mo-Rez) · Drug: Bevacizumab

  • Active comparator
    Platinum doublet + Bevacizumab

    Participants will receive platinum doublet chemotherapy (carboplatin with paclitaxel, gemcitabine, or pegylated liposomal doxorubicin \[PLD\]) and bevacizumab, followed by bevacizumab maintenance therapy.

    Drug: Carboplatin · Drug: Paclitaxel · Drug: Gemcitabine · Drug: Pegylated liposomal doxorubicin (PLD) · Drug: Bevacizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) by BICR

    PFS is defined as the time from the date of randomization to the date of first documented disease progression (PD) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) by Blinded independent central review (BICR) assessment or death from any cause, whichever occurs first.

    Time frame: Up to approximately 191 weeks

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from the date of randomization to the date of death due to any cause.

    Time frame: Up to approximately 343 weeks

  2. PFS by investigator assessment

    PFS is defined as the time from the date of randomization to the date of first documented PD per RECIST 1.1 by investigator assessment or death from any cause, whichever occurs first.

    Time frame: Up to approximately 343 weeks

  3. Time to Second Progression (PFS2)

    PFS2 is defined as the time from the date of randomization to the date of first documented investigator-assessed clinical or radiographical progression following the first subsequent anticancer therapy and after the progression event used for the primary variable PFS, or death from any cause, whichever occurs first.

    Time frame: Up to approximately 343 weeks

  4. Objective response rate (ORR) by investigator assessment

    ORR is defined as the percentage of participants with a complete response (CR) or partial response (PR) per RECIST 1.1 by investigator assessment.

    Time frame: Up to approximately 343 weeks

  5. Duration of Response (DOR) by investigator assessment

    DOR is defined as the time from the date of first documented objective response (CR or PR) per RECIST 1.1 by investigator assessment to the date of first documented PD per RECIST 1.1 by investigator assessment or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 343 weeks

  6. ORR by BICR

    ORR is defined as the percentage of participants with a CR or PR per RECIST 1.1 by BICR.

    Time frame: Up to approximately 343 weeks

  7. DOR by BICR

    DOR is defined as the time from the date of first documented objective response (CR or PR) per RECIST 1.1 by BICR assessment to the date of first documented PD per RECIST 1.1 by BICR or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 343 weeks

  8. Time to first subsequent therapy (TFST)

    TFST is defined as the time from the date of randomization to the date of initiation of subsequent therapy or death from any cause, whichever occurs first.

    Time frame: Up to approximately 343 weeks

  9. Time to second subsequent therapy (TSST)

    TSST is defined as the time from the date of randomization to the date of initiation of second subsequent therapy or death from any cause, whichever occurs first.

    Time frame: Up to approximately 343 weeks

  10. Number of participants with Treatment-emergent adverse event (TEAEs), Adverse event of special interest (AESIs) and Treatment-emergent serious adverse event (TESAEs)

    Time frame: Up to approximately 343 weeks

  11. Number of participants with TEAEs leading to dose modifications or study intervention discontinuation

    Time frame: Up to approximately 343 weeks

  12. Number of participants with changes in vital signs, laboratory tests (hematology and clinical chemistry), and Electrocardiogram (ECG)

    Time frame: Up to approximately 343 weeks

  13. Change from baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) score

    The EORTC QLQ-C30 includes 30-item questionnaire for evaluating the health-related quality of life (HRQoL) of participants participating in cancer clinical studies. The following domains will be measured: Global health status (GHS)/ Quality of Life (QoL), physical functioning, role functioning. Participants responses on these items are averaged and then transformed to scores, ranging from 0 to 100. Higher score indicates better functioning or a better . overall state of health.

    Time frame: Up to approximately 343 weeks

  14. Change from baseline in EORTC QLQ-Ovarian Cancer Module (OV28) score

    The EORTC QLQ-OV28 includes a 28-item questionnaire for evaluating ovarian cancer-specific symptoms and concerns in participants of cancer clinical studies. These include items that assess symptoms in the abdominal/gastrointestinal domain. Scores are averaged and transformed to a 0 to 100 scale; higher scores indicate a greater symptom burden, while lower scores reflect fewer symptoms.

    Time frame: Up to approximately 343 weeks

  15. Time to deterioration (TTD) of EORTC QLQ-C30

    TTD is defined as the time from the date of randomization to the first confirmed clinically meaningful deterioration on any of the following EORTC QLQ-C30 domains: physical functioning, role functioning and Global Health Status (GHS)/ Quality of Life (QoL).

    Time frame: Up to approximately 343 weeks

  16. Time to deterioration (TTD) of EORTC QLQ-OV28

    TTD is defined as the time from the date of randomization to the first confirmed clinically meaningful deterioration on the abdominal /gastrointestinal symptom domain of the EORTC QLQ-OV28.

    Time frame: Up to approximately 343 weeks

  17. Serum concentration of Mo-Rez

    Time frame: Up to approximately 343 weeks

  18. Number of participants with Antidrug antibody (ADA) and Neutralizing Antibody (NAb) against Mo-Rez

    Time frame: Up to approximately 343 weeks

  19. Titers of ADA against Mo-Rez

    Time frame: Up to approximately 343 weeks

07

Study locations

9 of 9 sites recruiting
  • GSK Investigational Site
    Newcastle, New South Wales 2298, Australia
    Recruiting
  • GSK Investigational Site
    Toronto, Ontario M5G 1Z5, Canada
    Recruiting
  • GSK Investigational Site
    Montreal, Quebec H4A 3J1, Canada
    Recruiting
  • GSK Investigational Site
    Hokkaido, 003-0804, Japan
    Recruiting
  • GSK Investigational Site
    Hyōgo, 673-8558, Japan
    Recruiting
  • GSK Investigational Site
    Ibaraki, 305-8576, Japan
    Recruiting
  • GSK Investigational Site
    Seoul, 03722, South Korea
    Recruiting
  • GSK Investigational Site
    Seoul, 135-710, South Korea
    Recruiting
  • GSK Investigational Site
    Seoul, 138-736, South Korea
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for May 2030, 44 months after the start.

Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's planned 44 months is close to that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2026
First posted
Jul 6, 2026
StartActual
Sep 8, 2026
Primary completionEst.
May 21, 2030
CompletionEst.
Apr 22, 2033
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 30, 2026
Sites
8 sites added — first sites in Australia, Canada and South Korea. GSK Investigational Site is now Recruiting
Show 8 added (3 South Korea, 2 Canada, 2 Japan, 1 Australia)
  • GSK Investigational Site · Newcastle, Australia
  • GSK Investigational Site · Toronto, Canada
  • GSK Investigational Site · Montreal, Canada
  • GSK Investigational Site · Hyōgo, Japan
  • GSK Investigational Site · Seoul, South Korea
  • GSK Investigational Site · Seoul, South Korea
  • GSK Investigational Site · Seoul, South Korea
  • GSK Investigational Site · Ibaraki, Japan
across 2 updates, Sep 30, 2026 – Oct 1, 2026
Start date
Sep 22, 2026→Sep 8, 2026 (actual)
Sep 30, 2026
Show all 2 updates
  1. Oct 1, 2026
    1 site added
    Show site
    • GSK Investigational Site · Ibaraki, Japan
  2. Sep 30, 2026
    Not yet recruiting→Recruiting
    7 sites added — first sites in Australia, Canada and South Korea. GSK Investigational Site is now Recruiting
    Show 7 added (3 South Korea, 2 Canada, 1 Australia, 1 Japan)
    • GSK Investigational Site · Newcastle, Australia
    • GSK Investigational Site · Toronto, Canada
    • GSK Investigational Site · Montreal, Canada
    • GSK Investigational Site · Hyōgo, Japan
    • GSK Investigational Site · Seoul, South Korea
    • GSK Investigational Site · Seoul, South Korea
    • GSK Investigational Site · Seoul, South Korea
    Start date Sep 22, 2026→Sep 8, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07684612
Lead sponsor
GlaxoSmithKline
Collaborators
GOG, ENGOT, APGOT
Responsible party
Sponsor
First posted
Jul 6, 2026
Start date
Sep 8, 2026
Primary completion
May 21, 2030 (estimated)
Completion
Apr 22, 2033 (estimated)
Last update
Oct 1, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mocertatug rezetecan

Start the discussion